Compass Therapeutics (CMPX) reported a Q4 net loss Thursday of $0.09 per diluted share, narrower than a loss of $0.11 a year earlier.
Analysts polled by FactSet expected a loss of $0.08.
As expected, no revenue for the quarter ended Dec. 31 was reported.
As of Dec. 31, the company said it had $209 million in cash and marketable securities, which will likely finance operations into 2028.